| About the author: |
V. A. Turkina, N. Ye. Chemodurova, H. V. Pryzyglei, Y. B. Кuzminov |
| Heading |
EXPERIMENTAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of this study was to establish maternal safety of topical preparation containing 5 % minoxidil, as well as safety for fetal development, fetus-maternal functional responses in experiments with laboratory rats using doses and methods of administration recommended by the manufacturer. Based on the results obtained under these experimental conditions, a lotion containing 5 % minoxidil does not cause changes to the reproductive system of rats and does not demonstrate embryotoxic effect. |
| Tags |
minoxidil, androgenetic alopecia, embryotoxic effect |
| Bibliography |
- Chiavaroli V, Derraik JGB, Hofman PL, Cutfield WS. Born large for gestational age: bigger is not always better. The Journal of Pediatrics. 2016;170:307–11.
- Choi N, Shin S, Song S, Sung J-H. Minoxidil promotes hair growth through stimulation of growth factor release from adipose-derived stem cells. International Journal of Molecular Sciences. 2018;19(3):691.
- European Union. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union. 2010;L276/33:33–79.
- Gaber MA, Doma HE. The psychosocial effect of androgenetic alopecia in males and females. Menoufia Med J . 2021;34:87–92.
- Goren A, Kovacevic M, McCoy J, Shapiro J. Minoxidil dose response study in female pattern hair loss patients determinedto be non-responders to 5 % topical Minoxidil. Journal of Investigative Dermatology. 2017;137(5):S144.
- Kabir Y, Goh C. Androgenetic alopecia. Journal of the Egyptian Women's Dermatologic Society. 2013;10(3):107–16.
- Koh YP, Tian EA, Oon HH. New changes in pregnancy and lactation labelling: Review of dermatologic drugs. International Journal of Women's Dermatology. 2019;5(4):216–26.
- Milam EC, Rieder EA. An Approach to Cosmeceuticals. J Drugs Dermatol. 2016;15(4):452–6.
- Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation. Journal of the American Academy of Dermatology. 2014; 70(3).
- Product monograph. Hair Regrowth Treatment Minoxidil Topical Solution USP [Internet]. Toronto, 2016 December 22. Available from: https://pdf.hres.ca/dpd_pm/00037622.PDF
- Savić S, Paunović J. Safety of cosmetic products in the light of European legislation: Cosmetic Regulation (EC) No 1223/2009. Arhiv za farmaciju. 2018;68(5):911–933.
- Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-Label Use of Topical Minoxidil in Alopecia: A Review. Am J Clin Dermatol. 2019;20(2):237–50.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]. Drug Design, Development and Therapy. 2020;14:575–6.
- Tai T, Kochhar A. Physiology and Medical Treatments for Alopecia. Facial Plastic Surgery Clinics of North America. 2020;28(2):149–59.
- Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 2016;7(50):82074–84.
|
| Publication of the article |
«World of Medicine and Biology» №2(76), 2021 year, 248-251 pages, index UDK 615.451.3.263.62:615.9:611.013.9 |
| DOI |
10.26724/2079-8334-2021-2-76-248-251 |
